Bulk Pharmaceutical API Sources for DEXFERRUM

Bulk Pharmaceutical API Sources for DEXFERRUM

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		105075
NovoSeek		522651
AAA Chemistry		AR-1J0769

Bulk Active Pharmaceutical Ingredient (API) Sources for DEXFERRUM

Last updated: February 19, 2026

DEXFERRUM, an intravenous iron dextran complex used to treat iron deficiency anemia, relies on consistent and compliant sourcing of its bulk active pharmaceutical ingredient (API). The API, a complex of ferric hydroxide with a high molecular weight polysaccharide dextran, requires stringent quality control throughout its manufacturing process to ensure safety and efficacy. This analysis identifies key global API manufacturers capable of producing iron dextran complexes, examining their regulatory standing, production capacity, and potential supply chain considerations relevant to DEXFERRUM.

What are the primary regulatory bodies governing API production for DEXFERRUM?

The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the primary regulatory bodies overseeing the manufacturing of APIs for pharmaceuticals like DEXFERRUM. Compliance with current Good Manufacturing Practices (cGMP) is mandatory.

• FDA: Requires manufacturers to register their facilities and undergo regular inspections. Drug Master Files (DMFs) submitted to the FDA provide confidential detailed information about facilities, processes, and materials used in manufacturing, processing, packaging, and storing the API.
• EMA: Operates under the European Union’s pharmaceutical legislation. Manufacturers must comply with EU GMP guidelines, and their APIs are assessed as part of the marketing authorization application (MAA) for the finished drug product. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often utilized.

Other national regulatory agencies, such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada, also play a role depending on the target markets for DEXFERRUM.

Which manufacturers are key suppliers of iron dextran API?

Several global pharmaceutical ingredient manufacturers specialize in iron-based APIs, including iron dextran complexes. These companies possess the technical expertise and regulatory compliance necessary for producing such complex molecules.

• Central Drug House (P) Ltd. (CDH): An Indian-based manufacturer with a long history in producing a wide range of pharmaceutical chemicals. CDH has capabilities in producing iron-based APIs. Their facility in India is designed to meet international quality standards.
  • Product Offering: Iron Dextran API.
  • Regulatory Status: CDH generally adheres to cGMP guidelines, and their products are often used in markets with established regulatory frameworks. Specific DMF filings for iron dextran API would need to be verified.
  • Capacity: While specific capacity figures are proprietary, CDH is known for its significant production scale for various APIs, suggesting it can accommodate substantial demand for iron dextran.
• Amresco LLC: A US-based supplier of laboratory chemicals and reagents that also offers pharmaceutical ingredients. Amresco's portfolio includes various iron compounds.
  • Product Offering: May include iron dextran or components for its synthesis.
  • Regulatory Status: Amresco emphasizes quality control and cGMP compliance for its pharmaceutical grade products. Verification of specific DMFs or regulatory filings for iron dextran API would be necessary.
  • Capacity: Typically supplies research and development quantities, but can scale for commercial production based on demand and contractual agreements.
• Various Chinese Manufacturers: China has emerged as a significant global supplier of APIs, including iron compounds. Numerous manufacturers in China produce iron dextran. Due diligence is critical to identify those with robust cGMP compliance and established regulatory track records.
  • Examples (generic categories, specific company verification needed): Companies located in key pharmaceutical manufacturing hubs like Jiangsu, Zhejiang, and Shandong provinces.
  • Product Offering: Iron Dextran API.
  • Regulatory Status: Many Chinese API manufacturers hold FDA registrations and have filed DMFs. However, the quality and regulatory adherence can vary significantly, necessitating thorough audits and verification.
  • Capacity: Chinese manufacturers often have large-scale production capabilities, allowing them to meet high volume demands.
• European Manufacturers: While specific producers of iron dextran API are less publicly detailed due to competitive dynamics, European manufacturers adhere to stringent EMA and national regulatory standards. These firms often focus on high-value, complex APIs.
  • Product Offering: Iron Dextran API.
  • Regulatory Status: High adherence to cGMP and EMA guidelines is standard. CEPs are common.
  • Capacity: Typically geared towards meeting the demands of the European and North American markets.

Table 1: Potential Iron Dextran API Suppliers and Considerations

Manufacturer/Region	Primary Location	Key Product	Regulatory Focus	Capacity Indication	Notes
Central Drug House (CDH)	India	Iron Dextran API	cGMP, international standards	Significant	Established producer of pharmaceutical chemicals.
Amresco LLC	USA	Iron Dextran API	cGMP, pharmaceutical grade	Scalable	Known for laboratory chemicals, with pharmaceutical ingredient capabilities.
Chinese Manufacturers	China	Iron Dextran API	cGMP, FDA DMFs, varies by producer	High Volume	Wide range of capabilities; requires stringent supplier qualification.
European Manufacturers	Europe	Iron Dextran API	EMA cGMP, national regulations, CEPs	Moderate to High	Focus on high-quality, complex APIs; subject to strict EU regulatory oversight.

What are the critical quality attributes and specifications for iron dextran API?

Iron dextran API is a complex mixture, and its quality is defined by several critical attributes that impact the safety and efficacy of the final DEXFERRUM product.

• Iron Content: The total iron content must fall within a specified range. This is crucial for achieving the correct therapeutic dose. Typical specifications are around 40-50% elemental iron by weight.
• Molecular Weight Distribution of Dextran: The dextran component has a high average molecular weight (typically >70,000 Daltons) and a defined distribution. This influences the pharmacokinetics and potential for hypersensitivity reactions. Gel permeation chromatography (GPC) is used for analysis.
• Free Iron: The level of non-complexed or loosely bound iron must be extremely low. Free ferric iron can contribute to oxidative stress and toxicity. Assays for free iron are critical. Limits are typically in the parts per million (ppm) range.
• Dextran Purity: The dextran used must be of high purity, free from contaminants like endotoxins and heavy metals. Microbiological testing for bioburden and bacterial endotoxins is essential, with strict limits for intravenous administration.
• pH and Osmolality: The API solution must have a controlled pH (typically between 3.5 and 5.0) and osmolality to ensure compatibility with intravenous administration and minimize irritation.
• Stability: The API must demonstrate stability under defined storage conditions, with no significant degradation of iron or dextran components over its shelf life. Forced degradation studies are performed to assess potential degradation pathways.
• Absence of Pyrogens and Endotoxins: As an injectable product, the API must be free from pyrogenic substances, particularly bacterial endotoxins. Limulus Amebocyte Lysate (LAL) testing is standard.

These specifications are typically detailed in pharmacopoeial monographs (e.g., United States Pharmacopeia, European Pharmacopoeia) and in the manufacturer's DMF.

How does the complexity of iron dextran API synthesis impact supply chain reliability?

The production of iron dextran API is a multi-step process involving the reaction of ferric salts with dextran under specific conditions, followed by purification. This complexity introduces several potential points of failure in the supply chain.

• Raw Material Sourcing: Sourcing high-quality, pharmaceutical-grade dextran and iron salts is paramount. Fluctuations in the availability or quality of these raw materials can disrupt production. Dextran itself is derived from sugar, introducing a dependency on agricultural supply chains.
• Process Control: Maintaining precise control over reaction parameters (temperature, pH, time, reagent ratios) is critical for achieving the desired molecular weight distribution and complexation. Deviations can lead to batch failures or substandard API.
• Purification Challenges: Separating the desired iron dextran complex from unreacted starting materials, by-products, and low molecular weight dextrans requires sophisticated purification techniques, such as ultrafiltration. Inefficient purification can lead to impurities affecting safety and efficacy.
• Scale-Up Difficulties: Transitioning from laboratory or pilot-scale production to commercial manufacturing can present challenges in maintaining consistent quality and yield.
• Regulatory Hurdles: Any change in the manufacturing process, raw material supplier, or production site requires rigorous validation and regulatory re-approval, which can be time-consuming and costly. This complexity can limit the number of qualified manufacturers.
• Geopolitical and Economic Factors: As with many APIs, concentration of manufacturing in specific regions (e.g., China, India) can expose the supply chain to geopolitical risks, trade disputes, and logistical disruptions.

These factors necessitate robust supplier qualification, ongoing quality agreements, and potentially dual-sourcing strategies to mitigate supply chain risks for DEXFERRUM.

What are the key considerations for selecting an API supplier for DEXFERRUM?

Selecting a reliable and compliant API supplier is crucial for the continued production of DEXFERRUM. Key considerations extend beyond price to encompass quality, regulatory adherence, and long-term partnership potential.

1. Regulatory Compliance and Documentation:
   • cGMP Certification: The manufacturer must have a proven track record of operating under cGMP guidelines, verified by regular audits and inspections from regulatory authorities (FDA, EMA).
   • DMF Availability: A comprehensive and up-to-date Drug Master File (DMF) filed with relevant regulatory agencies is essential. This document provides critical details on manufacturing processes, quality controls, and stability data.
   • Audit History: A review of the supplier’s audit history, including past findings from regulatory agencies and customer audits, is vital.
2. Quality Management System (QMS):
   • Robust QMS: The supplier must demonstrate a well-established and effective Quality Management System covering all aspects of API production, from raw material control to finished product release.
   • Change Control Procedures: A clear and robust change control process is necessary to ensure that any proposed changes to the manufacturing process, materials, or facilities are evaluated for their impact on API quality and are communicated to the customer.
3. Technical Capabilities and Manufacturing Process:
   • Process Understanding: The supplier should have a deep understanding of the complex iron dextran synthesis and purification process.
   • Analytical Capabilities: The supplier must possess advanced analytical capabilities to perform all required quality control tests and to support process development and validation.
   • Capacity and Scalability: The supplier must demonstrate sufficient production capacity to meet current and projected demand for DEXFERRUM and have the ability to scale up production if necessary.
4. Supply Chain Security and Risk Management:
   • Raw Material Sourcing: Transparency in the supplier’s raw material sourcing and qualification process is important. Understanding the origin and quality control of dextran and iron salts is critical.
   • Business Continuity Planning: The supplier should have a business continuity plan in place to address potential disruptions (e.g., natural disasters, geopolitical events, pandemics).
   • Geographic Diversification (if applicable): While challenging for complex APIs, exploring suppliers in different geographic regions can mitigate certain risks.
5. Financial Stability and Commercial Viability:
   • Financial Health: Assessing the financial stability of the potential supplier ensures their long-term ability to produce and supply the API.
   • Intellectual Property: Understanding any IP considerations related to the manufacturing process is important.
6. Communication and Partnership:
   • Transparency and Responsiveness: Open and timely communication regarding production status, quality issues, and regulatory updates is crucial.
   • Collaborative Approach: A willingness to collaborate on quality improvements, process optimization, and regulatory submissions fosters a strong partnership.

Table 2: API Supplier Selection Criteria for DEXFERRUM

Criterion	Importance Level	Key Assessment Areas
Regulatory Compliance	Critical	cGMP certification, FDA/EMA DMFs, inspection records, CEPs (if applicable)
Quality Management System	Critical	Robust QMS, change control, deviation management, CAPA, supplier qualification program
Technical Expertise	High	Process understanding, analytical capabilities, R&D support, validation expertise
Production Capacity	High	Current capacity, scalability, lead times, production scheduling flexibility
Supply Chain Security	High	Raw material sourcing strategy, business continuity plans, site security, logistics management
Financial Stability	Medium	Creditworthiness, financial reporting, investment in facilities
Cost and Commercial Terms	Medium	Pricing structure, payment terms, contract flexibility
Communication & Support	High	Responsiveness, technical support, proactive communication, partnership approach

How do patent landscapes impact API sourcing for DEXFERRUM?

The patent landscape for iron dextran formulations and manufacturing processes can indirectly influence API sourcing. While patents may not directly cover the bulk API itself, they can protect specific aspects of its production, purification, or use in particular drug products.

• Process Patents: Patents covering novel or improved methods of synthesizing or purifying iron dextran could restrict certain manufacturing routes for API producers. Manufacturers may need to operate under licenses or develop non-infringing processes.
• Formulation Patents: Patents on specific DEXFERRUM formulations might indirectly influence API requirements if they stipulate particular physical characteristics or purity profiles for the API to achieve the patented formulation's benefits.
• Method of Use Patents: Patents claiming specific uses of iron dextran, while not directly related to API manufacturing, can affect market demand and thus influence API production volumes.

API manufacturers must remain aware of the patent landscape relevant to their production methods and raw materials to avoid infringement. For pharmaceutical companies sourcing API, understanding these patents helps in assessing the long-term IP freedom of their API supply chain and potential risks associated with specific suppliers whose processes might be challenged. The generic nature of iron dextran as a therapeutic class generally means that fundamental patents have expired, but specific process improvements or novel formulations can still be protected.

Key Takeaways

• API Complexity: Iron dextran API production is technically demanding, requiring specialized manufacturing processes and stringent quality control to manage molecular weight distribution, iron complexation, and impurity profiles.
• Regulatory Scrutiny: Compliance with FDA and EMA cGMP standards is non-negotiable for API suppliers. Robust documentation, including DMFs, is essential.
• Supplier Landscape: Key suppliers include established entities in India (e.g., CDH), US-based suppliers (e.g., Amresco), and a significant number of manufacturers in China, alongside specialized European producers. Thorough supplier qualification is imperative.
• Quality Attributes: Critical quality attributes for iron dextran API include precise iron content, defined dextran molecular weight, minimal free iron, absence of pyrogens, and controlled pH/osmolality.
• Supply Chain Risks: Raw material sourcing, process control, purification challenges, and geopolitical factors represent significant risks to supply chain reliability.
• Supplier Selection: Beyond cost, selection criteria must prioritize regulatory compliance, quality systems, technical capabilities, supply chain security, and collaborative potential.
• Patent Influence: While fundamental patents on iron dextran may have expired, process and formulation patents can still impact API manufacturing and sourcing strategies.

Frequently Asked Questions

1. Are there specific pharmacopoeial monographs that define the quality standards for iron dextran API? Yes, monographs exist in the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), which define critical quality attributes, analytical methods, and acceptance criteria for iron dextran.
2. What is the typical lead time for securing a supply of iron dextran API from a new manufacturer? The lead time can vary significantly, but typically ranges from 3 to 12 months. This includes supplier qualification, audits, initial batch production, analytical testing, and regulatory documentation review.
3. How can a company ensure the consistency of iron dextran API quality from batch to batch from a chosen supplier? Consistency is ensured through robust quality agreements, regular supplier audits, stringent incoming material testing, review of supplier's batch records, and ongoing monitoring of supplier's performance metrics.
4. What are the main challenges in ensuring a secure supply chain for iron dextran API, especially concerning raw material sourcing? Challenges include the availability and consistent quality of pharmaceutical-grade dextran and iron salts, potential supply chain disruptions from a limited number of raw material producers, and the complex synthesis requiring specialized inputs.
5. Can a company producing a generic version of DEXFERRUM use an API from any manufacturer that produces iron dextran API? No, the API must be sourced from a manufacturer that complies with the cGMP standards of the target market's regulatory agencies (e.g., FDA, EMA) and has the necessary regulatory filings (e.g., DMF) accepted by those agencies. The API quality must also meet the specifications of the finished drug product.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/compliance-regulation/good-manufacturing-practice

[3] United States Pharmacopeia. (n.d.). General Chapters: Bacterial Endotoxins Tests. Retrieved from USP website (Specific chapter access requires subscription).

[4] European Pharmacopoeia. (n.d.). Iron Dextran Monograph. Retrieved from Ph. Eur. website (Specific monograph access requires subscription).

[5] Central Drug House (P) Ltd. (n.d.). Products. Retrieved from CDH website (Product details may require direct inquiry).

[6] Amresco LLC. (n.d.). Pharmaceutical Ingredients. Retrieved from Amresco website (Product specifics and regulatory status may require direct inquiry).